Pembrolizumab is well-tolerated and shows promising antitumor activity and early survival rates among patients with PD-L1–positive cervical squamous cell cancer, according to preliminary results of the KEYNOTE-028 trial.
Among women previously treated with neoadjuvant chemotherapy followed by debulking surgery for advanced epithelial ovarian cancer, adding intraperitoneal to intravenous administration of postsurgical chemotherapy appears to be associated with a lower rate of disease progression.
ASCO has released a clinical practice guideline on invasive cervical cancer. For the first time, ASCO created the guideline based on resource availability, tailoring recommendations to support basic- or limited-resource settings.
The American Society of Clinical Oncology released a statement calling for the rapid expansion of use of the human papillomavirus (HPV) vaccine to help protect thousands of people from HPV-associated cancers.
The combination of sentinel lymph node mapping and use of uterine intraoperative restrictive frozen section in patients with low-grade endometrial cancer can reduce the rate of complete lymphadenectomy without reducing the detection of lymphatic metastasis.
Combining three markers of homologous recombination deficiency into a single score may improve treatment decisions for women with ovarian cancer, according to a study reported at the 2016 SGO Annual Meeting.
Assignment to a dose-dense regimen of paclitaxel given weekly did not prolong progression-free survival compared with paclitaxel given every 3 weeks in a group of patients with ovarian cancer treated with or without bevacizumab.